UltraSight, formerly named On-Sight Medical, a digital health firm focusing on cardiac imaging, said Tuesday it has closed a $13 million Series B funding round that will help the startup advance clinical trials for its AI-based technology.
The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round, the company said in a statement.
UltraSight’s AI-based software enables clinicians to use ultrasound devices and conduct cardiac sonography imaging at the point of care, helping more patients be diagnosed and treated.
Point of care ultrasound allows medical professionals with no prior sonography training to diagnose patients wherever they are including clinics, community hospitals, ambulances and remote settings. Currently, cardiac sonography is a skill that takes years to acquire and requires daily practice to maintain high proficiency. UltraSight aims to change that by offering clinicians with no prior sonography training automated guidance and quality assessment for conducting ultrasound scans.
“We see a future where ultrasound is readily available to assess any patient, anywhere and by any healthcare professional. Simplifying ultrasound is critical to providing fast, effective care,” said Andrew Cleeland, CEO of Fogarty Innovation. “By making ultrasound ubiquitous, UltraSight has the potential to bring the benefits of cardiac imaging to more healthcare professionals and new care settings.”
UltraSight also said it has made a number of new appointments to its medical and scientific board including that of Al Lojewski, former general manager of cardiology solutions at GE Healthcare; Dr Laurance Grossman, radiologist at Cleveland Clinic; and Andrew Cleeland, CEO of Fogarty Innovation.
The company’s technology was chosen by the Ramon Foundation to accompany Eytan Stibbe, the second Israeli astronaut, on his 2022 mission to the International Space Station.
The technology will be tested in the space station, where untrained crew members will perform ultrasound scans with remote help and guidance in real-time and receive expert analysis and interpretation. The success of this test can provide vital and meaningful medical information in the field of space medicine, since long missions to space can be dangerous to the cardiovascular system, UltraSight said. Israel Aerospace Medicine Institute is a partner in the study.